What was filed
Jagsonpal Pharmaceuticals told the exchanges it has signed a definitive agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited, a Mumbai-based company focused on the sale and distribution of pharmaceutical products to hospitals. The current directors of Aequitas will retain the remaining 15% and continue with the business. Per the filing, the consideration will be funded from Jagsonpal's internal accruals, and the transaction is subject to customary closing conditions, with completion expected by 15 July 2026.
Why it matters to a holder
The company framed the deal as its strategic entry into the hospital segment — a channel it has not directly served before. Management described the move as a shift from a legacy retail prescription player toward an omnichannel specialty healthcare business, and pointed to Aequitas' existing relationships across leading hospital chains as a ready platform. For a holder, the filing changes the shape of the business mix rather than the scale of the company: the target is small relative to a multi-decade pharma operation, and the stated rationale is access to institutional sales relationships rather than near-term revenue addition.
The structure
This is a controlling but not full acquisition: by leaving 15% with the founding directors who stay on, Jagsonpal retains continuity of the people who built the hospital relationships. The company said J Sagar & Associates advised Jagsonpal and Noverra Partners advised Aequitas. The terms beyond stake, price and timeline are not detailed in the press release.